OKMETIC´S FINANCIAL STATEMENTS FOR 1 JANUARY – 31 DECEMBER 2009

At the end of the year, cash and cash equivalents amounted to 7.3 million euro (18.0 million euro). On 31 December 2009, the group´s cash and cash equivalents exceeded the interest-bearing liabilities by 4.8 million euro (on 31 December 2008 liabilities were 0.6 million higher than cash and cash equivalents).

Return on equity amounted to -1.0 percent (12.1% positive). The group´s equity ratio strengthened, amounting to 78.9 percent (62.8%). Equity per share was 2.89 euro (2.98 euro).

INVESTMENTS

In 2009, Okmetic´s capital expenditure amounted to 1.7 million euro (2.6 million euro). The majority of the capital expenditure focused on increasing the company´s sensor wafer production capacity and on regular maintenance.

PRODUCT DEVELOPMENT

The company expensed 2.1 million euro (2.3 million euro) in long-term product development projects in 2009. Product development costs accounted for 3.9 percent (3.3%) of net sales. Product development costs have not been capitalised.

Okmetic´s research and development efforts are geared towards increasing its technological expertise and competitiveness. Research and development focuses on developing new products and improving the features and the production process performance of the existing products.

Okmetic engaged in several strategic research projects with customers, research institutes and other partners and participated both in national technology programmes funded by Tekes, the leading Finnish funding agency for technology and innovation, and international EU-funded programmes. In 2009 Okmetic launched a new CAP-wafer and extended the performance of SOI product family and 200 mm sensor products.

PERSONNEL

The personnel´s expertise and well-being are Okmetic´s strengths as well as preconditions for the realisation of the company´s strategy and success in the long term. The commitment to Okmetic by its personnel is demonstrated by the improvement of several operational results, the low absence rate and lively participation in the initiative scheme despite the adjustment actions affecting the personnel in the financial year.

On average, Okmetic employed 337 people in 2009 (2008: 364 and 2007: 362). At the end of the year, 296 of the group´s employees worked in Finland, 28 in the US and three in Japan. As a result of the personnel negotiations the number of the clerical workers was reduced by approximately 20 persons in the last quarter of the year.

Twenty-nine percent (29%) of the personnel were women and seventy-one percent (71%) were men.  Clerical workers accounted for forty percent (36%) and manual workers for sixty percent (64%). The average age of Okmetic´s employees was 41 (41) and the average length of employment was 9.6 (8.5) years.

Salaries and bonuses are based on the level of skills required in each position throughout the organisation. Salaries and bonuses amounted to 15.9 million euro (2008: 18.0 million euro and 2007: 18.1 million euro). The company´s parent company complies with the collective labour agreements of the Technology Industries of Finland.

All employee groups at Okmetic are eligible for an incentive scheme. Monthly targets are set for the manual workers' productivity, and the resulting bonuses are paid once a month. Clerical workers and management are paid bonuses according to targets relating to the group's profitability, financial situation and operative performance. The bonuses payable for meeting the group's financial targets account for 6 - 15 percent of the employees' annual income, at the most, depending on the personnel group. Operative targets are set individually from managerial level upwards. Any bonuses paid as a result of meeting these can account for no more than 6-15 percent of the managers' annual income. Based on the results achieved in 2009, bonuses were paid only to the employees.

ENVIRONMENTAL ISSUES

Okmetic recognises the environmental risks associated with its business. The company devises both a universal risk management plan and plans for individual processes. Ecologically sustainable operations boost Okmetic´s competitiveness and profitability.

Measures devised for eliminating environmental risks are integrated to Okmetic´s operational processes. Environmental considerations are also factored into the further development of products and business in line with continuous improvement principles. Planning preventive measures is fundamental to managing environmental risks.

Okmetic keeps an eye on developments in environmental legislation both in Finland and internationally, and adjusts its business to meet the latest regulations. For example, Okmetic follows the chemicals regulations of the European Union (REACH) and all Okmetic´s products meet the requirements set in the RoHS-directive.

Okmetic has ISO 9001:2000, TS 16949 and ISO 14001 certified quality and environmental systems, and the company's plants have been built with environmental considerations in mind. Okmetic expects its most important subcontractors and suppliers to comply with the ISO 9001:2000- and ISO 14001 -certifications.

Okmetic recognises that the use of its main raw material, polysilicon, has an important environmental impact. The company does not produce essential volumes of emissions or waste, and the resulting costs are not significant from a business point of view. On a day-to-day level, Okmetic strives to use materials, water and electricity as efficiently as possible. The company strives to recycle arising waste.

Okmetic had no major environmental non-conformities in 2009. The acceptable emission limit values set for waste water treatment were exceeded on two occasions. In these instances the recorded values were nevertheless only just over the acceptable limits and corrective measures were implemented expediently. Okmetic's environmental management system was found to meet the requirements of the company's demanding international customers. The company is not subject to emissions trading regulations.

The key figures on environmental protection at the Vantaa plant in 2009 are as follows:

Energy consumption (GWh): electricity 29.1 (28.6), district heating 2.5 (2.2) Water consumption (tm3): water 485 (520), waste water 365 (450) Waste volumes (t): hazardous waste 125 (230), landfill waste 68 (57), recycled waste 177 (190).

BUSINESS RISKS

The Okmetic´s silicon wafer sales are targeted at the sensor and semiconductor producers in electronics industry. The demand for semiconductor wafers is sensitive to economic fluctuations and changes in the market situation can be sudden and dramatic. The demand for sensor wafers is more stable. Irregular income recognition of significant technology projects in technology sales causes considerable variation in the results of the review periods. The success of the sales strategy hinges on trouble-free contract manufacturing.

Okmetic's share of the global silicon wafer market is around one percent and the market prices have a notable effect on the price development of Okmetic's products. The majority of sales are conducted in US dollars. The Japanese yen is another notable trading currency. Despite hedging, the company remains vulnerable to exchange rate fluctuations.

Great volumes of electricity are used in Okmetic's production. Despite hedging, the company is also vulnerable to fluctuations in the price of electricity.

SHARES AND SHAREHOLDERS

On 31 December 2009, Okmetic Oyj's paid-up share capital, as entered in the Finnish trade register, was 11,821,250.00 euro. The share capital is divided into 16,887,500 shares. The shares have no nominal value attached. Each share entitles its holder to one vote at general meetings. The company has one class of shares. The company's shares are included in the Finnish book-entry securities system.

Major shareholders on 31 Dec 2009

                                                            Shares, pcs Share, %    Outokumpu Oyj                                               2,705,000     16.0   Ilmarinen Mutual Pension Insurance Company                  1,533,626      9.1   OP-Suomi Arvo Equity Fund                                   1,185,401      7.0   Mandatum Life Insurance Company                               800,000      4.7   Etra Invest Oy Ab                                             500,000      3.0   The State Pension Fund                                        500,000      3.0   Varma Mutual Pension Insurance Company                        477,175      2.8   Arvo Finland Value Fund                                       400,000      2.4   Carnegie Share Fund                                           333,639      2.0   Finnish Industrial Investment Ltd.                            320,750      1.9  

Foreign investors and nominee accounts held by custodian

 banks                                                       3,885,372     23.0   Others                                                      4,246,537     25.1   Total                                                      16,887,500    100.0     

Shareholders by group on 31 Dec 2009

                                                            Shares, pcs Share, %    Corporations                                                4,288,222     25.4   Financial and insurance institutions                        2,457,669     14.6   Public organisations                                        2,537,001     15.0   Non-profit organisations                                      262,197      1.5   Households                                                  3,457,039     20.5 

Foreign investors and nominee accounts held by custodian

 banks                                                       3,885,372     23.0   Total                                                      16,887,500    100.0     

Distribution of shareholding on 31 Dec

 2009                                 Number of         % of    Shares,      % of share  Shares, pcs               shareholders shareholders        pcs         capital     1-100                              369         11.6     29,570             0.2   101-500                          1,364         43.0    417,608             2.5   501-1,000                          615         19.4    528,018             3.1   1,001-10,000                       750         23.7  2,224,286            13.2   10,001-100,000                      61          1.9  1,408,352             8.3   100,001-1,000,000                    9          0.3  3,573,725            21.2   Over 1,000,000                       4          0.1  8,705,941            51.5   Total                            3,172        100.0 16,887,500           100.0  

SHARE PRICE DEVELOPMENT AND TRADING

A total of 4.3 million shares (8.4 million shares) were traded between 1 January and 31 December 2009, representing 25.6 percent (49.5%) of the share total of 16.9 million. The lowest quotation of the year was 1.81 euro (2.15 euro) and the highest 3.20 euro per share (3.14 euro), with the average being 2.54 euro (2.63 euro). The closing quotation for the year was 3.20 euro (2.40 euro). At the end of the year, the market capitalisation amounted to 54.0 million euro (40.5 million euro).

Okmetic is listed on the Small Cap list of NASDAQ OMX Helsinki Ltd under the trading code OKM1V. According to the Global Industry Classification Standard (GICS), which the exchange uses, Okmetic Oyj is listed under the Information Technology sector. The company´s website can be found at www.okmetic.com . OWN SHARES

The company has not repurchased any of its own shares.

On 11 February 2010, the board of directors has decided on a purchase scheme of the company´s own shares, based on the authorisation given at the extraordinary general meeting on 6 November 2008. The aggregate number of shares repurchased will not be more than 280,000. The repurchase will start on 18 February 2010 at the earliest and it will end on 6 May 2010 at the latest.

THE BOARD OF DIRECTORS´AUTHORISATION TO DECIDE ON THE REPURCHASE AND/OR THE ACCEPTANCE AS PLEDGE OF THE COMPANY´S OWN SHARES

The shareholders participating in the extraordinary general meeting held on 6 November 2008 accepted the board of directors' proposal regarding the board's authorisation to repurchase the company's own shares as follows:

The aggregate number of shares repurchased on the basis of the authorisation cannot exceed 1,688,750 shares, which represents 10 percent of all the shares of the company. The company and its subsidiaries together cannot at any time own more than 10 percent of all of the company's registered shares.

Only unrestricted shareholders' equity can be used to repurchase the company's own shares under the authorisation. Own shares can be repurchased at a price determined by public trading on the day of repurchase or at another market-based price.

The board of directors decides the method of repurchasing the company's own shares as well as the other terms and conditions. Derivatives, for example, can be used in the repurchase. Shares can be repurchased independently of the shareholders' proportional share holdings (private placement). The authorisation will remain in force until the annual general meeting of spring 2010 and in any case not past 6 May 2010.

On 11 February 2010, the board of directors has decided to propose to the annual general meeting, which is to be held on 7 April 2010, that a similar authorisation for the repurchase and/or acceptance as pledge of the company´s own shares should be granted to the board of directors until the annual general meeting of spring 2011, but in any case not past 7 October 2011. The authorisation shall cancel the authorisation granted at the extraordinary general meeting of 6 November 2008 regarding the repurchase of the company´s own shares.

THE BOARD OF DIRECTORS´ AUTHORISATION TO DECIDE ON TRANSFERRING RIGHTS TO THE COMPANY´S OWN SHARES

The shareholders participating in the extraordinary general meeting held on 6 November 2008 accepted the board of directors' proposal regarding the board's authorisation to transfer rights to the company's own shares as follows:

The aggregate number of rights transferred on the basis of the authorisation cannot exceed 1,688,750 shares, which represents 10 percent of all the shares of the company.

The board of directors has the authority to decide on all the terms and conditions of the share issues. The authorisation is limited to transferring rights to the company's own shares as held by the company. The share issue can be carried out as a private placement. The board of directors can also cancel any shares it has repurchased. The authorisation will remain in force until further notice, although in any case not past 30 June 2013.

AUTHORISATION OF THE BOARD OF DIRECTORS TO INCREASE SHARE CAPITAL

On 11 February 2010, the board of directors decided to propose at the annual general meeting to be held on 7 April 2010 that the board should be granted the authority to decide on new issues and share entitlements according to the first paragraph of section 10 of the Finnish Companies Act as follows:

The aggregate number of shares issued on the basis of the authorisation cannot exceed 3,377,500 shares, which represents approximately 20 percent of all the shares of the company.

The board of directors has the authority to decide on all the terms and conditions concerning the issue of shares and other share entitlements. The authorisation relates to the issuance of new shares. Issuance of shares and other share entitlements can be carried out as a directed issue.

The authorisation is effective until the following annual general meeting of shareholders and shall not cancel the authorisation granted at the extraordinary general meeting of 6 November 2008 regarding the transfer of the company´s own shares.

The board of directors was granted similar authorisations at the annual general meetings held on 3 April 2008 and 2 April 2009.

On 25 January 2010, the board of directors has directed, in accordance with the authorisation granted on 2 April 2009, a share issue of 400,000 new shares to the company owned by the President and Deputy to the President.

CONVERTIBLE BONDS AND OPTION PROGRAMMES

Okmetic has no convertible bonds or option programmes at the moment.

MANAGEMENT AND AUDITOR

In 2009, Okmetic´s board of directors was made up of Henri Österlund as the chairman, Karri Kaitue as the deputy chairman, and Tapani Järvinen, Hannu Martola and Pekka Salmi as members of the board.

Kai Seikku has been acting as the President of Okmetic Oyj since 25 January 2010. Deputy to the President, Executive Vice President, Sales, Mikko Montonen handled the duties of President 27 October 2009 - 24 January 2010.  Antti Rasilo, M. Sc (Tech.) acted as the President until 27 October 2009.

In addition to the president, the group´s executive management group comprises Tapio Jämsä, Senior Vice President, Sourcing; Jaakko Montonen, Senior Vice President, Production; Mikko Montonen, Executive Vice President, Sales and Deputy to the President; Esko Sipilä, Senior Vice President, Finance; Markku Tilli, Senior Vice President, Research; Markus Virtanen, Senior Vice President, Human Resources; and Anna-Riikka Vuorikari-Antikainen, Senior Vice President, Product Development.

The company´s auditors are PricewaterhouseCoopers Oy, Authorised Public Accountants, with Markku Marjomaa, Authorised Public Accountant, acting as the principal auditor.

THE BOARD OF DIRECTORS´ PROPOSAL REGARDING DIVIDEND DISTRIBUTION

According to the financial statements dated 31 December 2009, the parent company´s distributable earnings amount to 15,971,251.05 euro. No significant changes have taken place in the company´s financial position after the end of the financial year.

The board of directors of Okmetic Oyj proposes to the annual general meeting that Okmetic Oyj pay a dividend of 0.05 euro per share for 2009, which, based on the 16,887,500 shares registered on 11 February 2010 and 400,000 shares registered in the directed share issue on 25 January 2010, amount to 864,375.00 euro.

CONDENSED FINANCIAL STATEMENTS AND TABLES 1 JANUARY - 31 DECEMBER 2009

ACCOUNTING POLICIES

This financial statement release has been prepared in accordance with IAS 34, Interim Financial Reporting.

In preparing this financial statement release, Okmetic has followed the same accounting policies as in the financial statements for 2008 except that the company has adopted the following new or revised standards as of 1 January 2009:

  - IAS 1 (Revised), Presentation of Financial Statements. The revised standard affects the way the income statement and the statement of changes in equity are presented. - IFRS 8, Operating Segments. The standard does not affect the information presented for segments, because the segment data provided by the group have always been based on the group's internal reporting structure. - IFRS 7 (Amendment), Enhancing Disclosures on Financial Instruments. The amendment requires enhanced disclosures about fair value measurement and liquidity risk. - IAS 1 (Amendment), Current Assets and Current Liabilities. As a result of the amendment the group reclassified derivatives in held for trading category as non-current in case they mature after 12 months and the group does not hold them primarily for trading purposes.  

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

   1,000 euro                                   1.10.-   1.10.-    1.1.-    1.1.-                                             31.12.09 31.12.08 31.12.09 31.12.08     Net sales                                    13,812   15,751   54,361   67,867   Cost of sales                               -12,602  -11,545  -47,883  -50,687   Gross profit                                  1,210    4,206    6,478   17,180   Other income and  expenses                                     -1,407   -3,097   -6,208   -8,704   Operating profit/loss                          -197    1,108      270    8,476   Financial income and  expenses                                          1   -2,432     -860   -2,900   Profit/loss before tax                         -196   -1,323     -590    5,576   Income tax                                     -148      206       77      248   Profit/loss for the  period                                         -344   -1,117     -513    5,825     Other comprehensive income:   Translation  differences                                      73      196     -220      560   Available-for-sale  financial assets                                  -    1,013        -      114   Other comprehensive  income for the period,  net of tax                                       73    1,210     -220      674     Total comprehensive  income for the period                          -271       93     -733    6,499   

Profit/loss for theperiod attributable to:

  Equity holders of the  parent company                                 -344   -1,117     -513    5,825   

Total comprehensive income attributable

 to:   Equity holders of the  parent company                                 -271       93     -733    6,499     Basic and diluted  earnings per share,  euro                                          -0.02    -0.07    -0.03     0.34  

CONDENSED CONSOLIDATED BALANCE SHEET

   1,000 euro                                                  Dec 31, Dec 31,                                                                 2009    2008     Assets     Non-current assets   Property, plant and equipment                                33,174  38,848   Other receivables                                             3,398   4,619   Total non-current assets                                     36,572  43,468     Current assets   Inventories                                                   7,164  10,753   Receivables                                                  10,950   9,289   Cash and cash equivalents                                     7,307  17,975   Total current assets                                         25,422  38,016     Total assets                                                 61,994  81,484     Equity and liabilities   Equity 

Equity attributable to equity holders of the parent company

  Share capital                                                11,821  11,821   Other equity                                                 36,921  38,568   Total equity                                                 48,742  50,389     Liabilities   Non-current liabilities                                       3,143  14,027   Current liabilities                                          10,109  17,068   Total liabilities                                            13,252  31,095     Total equity and liabilities                                 61,994  81,484    

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

    1,000 euro                                  Jan 1-       Jan 1-                                        Dec 31, 2009 Dec 31, 2008   

Cash flows from operating activities:

  Profit/loss before tax                        -590        5,576   Adjustments                                  7,183       11,272   Change in working capital                      289       -2,935   Interest received                              245          424 

Interest paid and other financial

  items                                         -812       -1,135   Tax paid                                        -1          -26   Net cash from operating activities           6,315       13,177    

Cash flows from investing activities:

   Proceeds from investing activities             641          469   Capital expenditure                         -1,694       -2,646   Net cash used in investing  activities                                  -1,053       -2,177   

Cash flows from financing activities:

Repayments of long-term borrowings -14,823 -4,748

  Payments of finance lease  liabilities                                   -117         -198   Dividends paid                                -844       -1,689   Net cash used in financing  activities                                 -15,784       -6,634   

Increase(+) / decrease(-) in cash

  and cash equivalents                       -10,523        4,365   Exchange rate changes                         -145          301  

Cash and cash equivalents at the

  beginning of the period                     17,975       13,308  

Cash and cash equivalents at the

 end of the period                            7,307       17,975    

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

      Equity attributable to equity holders of parent company

   1,000 euro      Share      Share      Trans-lation Fair      Retained  Total                 capi-tal   pre-mium    diffe-rences value     earnings  equity                                                     re-serve   Balance at  31 Dec 2008       11,821     20,115            635         -    17,818  50,389   Total  Comprehensive  income for  the period                                                -220                -513    -733   Dividend  distribution                                                      -844    -844   Equity  component of  convertible  loan notes                      -70                                        -70   Balance at  31 Dec 2009       11,821     20,045            415         -    16,461  48,742   Balance at  31 Dec 2007       11,821     20,185             75      -114    13,682  45,649   Total  Comprehensive  e income for  the period                                                 560       114     5,825   6,499   Dividend  distribution                                                    -1,689  -1,689   Equity  component of  convertible  loan notes                      -70                                        -70   Balance at  31 Dec 2008       11,821     20,115            635         -    17,818  50,389  

CHANGES IN PROPERTY, PLANT AND EQUIPMENT

     1,000 euro                                     Jan 1-       Jan 1-                                           Dec 31, 2009 Dec 31, 2008   

Carrying amount at the beginning of

 the period                                     38,848       43,355   Additions                                       1,448        2,773   Disposals                                           -         -537   Depreciation                                   -6,936       -7,041   Exchange differences                             -187          298 

Carrying amount at the end of the period 33,174 38,848

CHANGES IN FINANCIAL LIABILITIES

     1,000 euro                                Jan 1-       Jan 1-                                      Dec 31, 2009 Dec 31, 2008   

Carrying amount at the beginning of

  the period                                17,389       22,259  

Proceeds of loans from financial

  institutions                                   -          999  

Repayments of loans from financial

  institutions                             -13,806       -4,744   Repayments of subordinated loans            -928         -928  

Changes in finance lease

  liabilities                                 -117         -198   Carrying amount at the end of the                           1  period                                     2,538        7,389   DIVIDENDS PAID 

In April, the company distributed a dividend of 0.8 million euro of the profit accrued in 2008, representing a 0.05 euro dividend per share.

COMMITMENTS AND CONTINGENCIES

     1,000 euro                             Dec 31, 2009 Dec 31, 2008     Loans secured with collaterals                2,500       13,333   Collaterals                                   8,073       24,964   Off-balance sheet lease commitments              83          165     Capital commitments                             111          574   

Nominal values of derivative contracts

   Currency forward agreements                   1,385            -   Electricity derivatives                       2,520        2,961   Interest rate swaps                           6,429            -   

Fair values of derivative contracts

  Currency forward agreements                      -4            -   Electricity derivatives                        -258         -540   Interest rate swaps                             -49            -  

The contract price of the derivatives has been used as the nominal value of the underlying asset. Derivative contracts are for hedging.

RELATED PARTY TRANSACTIONS

Top management compensation during the period under review amounted to 1,497,000 euro (1,506,000 euro).

KEY FIGURES SHOWING FINANCIAL PERFORMANCE

    1,000 euro                               Jan 1-       Jan 1-                                     Dec 31, 2009 Dec 31, 2008     Net sales                                54,361       67,867 

Change in net sales compared to

  the previous year´s period, %             -19.9          5.0  

Export and foreign operations

 share of net sales, %                      95.4         95.6   Operating profit before  depreciation (EBITDA)                     7,206       15,517       % of net sales                         13.3         22.9   Operating profit                            270        8,476       % of net sales                          0.5         12.5   Profit/loss before tax                     -590        5,576       % of net sales                         -1.1          8.2   Return on equity, %                        -1.0         12.1   Return on investment, %                     0.0          9.9 

Non-interest-bearing liabilities 10,715 13,707

Net interest-bearing liabilities -4,770 -586

  Net gearing ratio, %                       -9.8         -1.2   Equity ratio, %                            78.9         62.8   Capital expenditure                       1,448        2,773       % of net sales                          2.7          4.1   Depreciation                              6,936        7,041   Research and development  expenditure 1)                            2,134        2,261       % of net sales                          3.9          3.3   

Average number of personnel during

  the period                                  337          364  

Personnel at the end of the period 327 363

1) Research and development expenditure has been presented in gross figures and only long-term projects based on research program have been taken into account.

 KEY FIGURES PER SHARE      Euro                                                   Dec 31 2009 Dec 31 2008   

Earnings per share basic and

 diluted                                                      -0.03        0.34   Equity per share                                              2.89        2.98   Dividend per share                                            0.05        0.05   Dividends/earnings, %                                       -164.7        14.5   Effective dividend yield, %                                    1.6         2.1   Price/earnings (P/E)                                        -105.4         7.0    

Share price performance (Jan 1-)

  Average trading price                                         2.54        2.63   Lowest trading price                                          1.81        2.15   Highest trading price                                         3.20        3.14 

Trading price at the end of the

  period                                                        3.20        2.40  

Market capitalisation at the end of the period, 1,000

 euro                                                        54,040      40,530    Trading volume (Jan 1-)   Trading volume, transactions                             4,316,320   8,355,374  

In relation to weighted average

  number of shares, %                                           25.6        49.5   Trading volume, euro                                    10,957,275  22,002,739  

The weighted average number of

shares during the period under

  review adjusted by the share issue                      16,887,500  16,887,500  

The number of shares at the end of

the period adjusted by the share

 issue                                                   16,887,500  16,887,500   QUARTERLY KEY FIGURES                                 10-12/09 7-9/09 4-6/09 1-3/09     Net sales                     13,812 12,171 13,538 14,841     Compared to previous    quarter %                     13.5  -10.1   -8.8   -5.8   Operating profit/loss           -197   -748    688    527     % of net sales                -1.4   -6.1    5.1    3.6   Profit/loss before tax          -196 -1,257     46    818     % of net sales                -1.4  -10.3    0.3    5.5     Net cash flow generated  from:  Operating activities           1,858    192  4,761   -496   Investing activities             -28    -87   -786   -152   Financing activities         -11,821    -22 -3,905    -37 

Increase/decrease in cash

and cash equivalents -9,991 83 70 -685

Personnel at the end of the

 period                           327    335    343    338                                   10-12/08 7-9/08 4-6/08 1-3/08     Net sales                     15,751 18,090 16,992 17,034 

  Compared to previous

   quarter %                    -12.9    6.5   -0.2    7.9   Operating profit               1,108  2,089  2,737  2,542     % of net sales                 7.0   11.5   16.1   14.9 

Profit/loss before tax -1,323 2,683 2,582 1,634

     % of net sales                -8.4   14.8   15.2    9.6    

Net cash flow generated

 from:  Operating activities           2,878  4,522  3,495  2,281   Investing activities            -716   -289   -841   -331   Financing activities          -1,912    -48 -4,616    -58 

Increase/decrease in cash

  and cash equivalents             250  4,185 -1,962  1,892    

Personnel at the end of the

  period                           363    361    370    359   

DEFINITIONS OF KEY FINANCIAL FIGURES

Operating profit before depreciation = Operating profit + depreciation

 (EBITDA)     Return on equity, % (ROE)            = Profit/loss for the period from                                         continuing operations x 100/                                        -----------------------------------------                                         Equity(Average for the period)    Return on investment, % (ROI)        = (Profit/loss before tax + interest and
                                        other financial expenses) x 100/                                        -----------------------------------------                                         Balance sheet total - non-interest                                         bearing liabilities(average for the                                         period)     Equity ratio, %                      = Equity x 100/                                        -----------------------------------------                                         Balance sheet total - advances received   
 Net interest-bearing liabilities       Interest-bearing liabilities - cash and
                                        cash equivalents     Net gearing ratio, %                 = (Interest-bearing liabilities - cash                                         and cash equivalents)x 100/                                        -----------------------------------------                                         Equity     Earnings per share                   = Profit/loss for the period attributable                                         to the equity holders of the parent                                         company/                                        -----------------------------------------                                         Adjusted weighted average number of                                         shares in issue during the period     Equity per share                     = Equity attributable to the equity                                         holders of the parent company/                                        -----------------------------------------                                         Adjusted number of shares at the end of                                         the period     Dividend per share                   = Dividend for the period/                                        -----------------------------------------                                         Adjusted number of shares at the end of                                         the period   
 Effective dividend yield, %          = Dividend per share x 100/
                                       -----------------------------------------                                         Trading price at the end of the period     Price/earnings ratio (P/E)           = Last adjusted trading price at the end                                         of the period/                                        -----------------------------------------                                         Earnings per share     Average trading price                = Total traded amount in euro/                                        -----------------------------------------                                         Adjusted number of shares traded during                                         the period   
 Market capitalisation at the end of  = Number of shares at the end of the
 the period                             period x trading price at the end of                                         the period     Trading volume                       = Number of shares traded during the                                         period/                                        -----------------------------------------                                         Weighted average number of shares                                         during the period  
All figures of the financial tables are rounded, and consequently the sum of individual figures can deviate from the presented sum figure.
In the written report, the figures in parenthesis refer to the corresponding period in the previous year.
The future estimates and forecasts in this financial statement release are based on company management´s current knowledge. Actual events and results may differ from the estimates presented here.
 OKMETIC OYJ  Board of directors  
For further information, please contact:
  President Kai Seikku, Okmetic Oyj, tel. +358 9 5028 0232, email: [email protected]  
Senior Vice President, Finance Esko Sipilä, Okmetic Oyj, tel. +358 9 5028 0286, email: [email protected]
Distribution:
 NASDAQ OMX Helsinki Principal media www.okmetic.com   
OKMETIC IN BRIEF
Take it higher
Okmetic is a technology company which supplies tailor-made silicon wafers for sensor and semiconductor industries and sells its technological expertise to the solar cell industry. Okmetic provides its customers with solutions that boost their competitiveness and profitability.
Okmetic's silicon wafers are part of a further processing chain that produces end products that improve human interaction and quality of life. Okmetic's products are based on high-tech expertise that generates added value for customers, innovative product development and an extremely efficient production process.
Okmetic has a global customer base and sales network, production plants in Finland and the US and contract manufacturers in Japan and China. Okmetic's shares are listed on NASDAQ OMX Helsinki under the code OKM1V. For more information on the company, please visit our website at www.okmetic.com.
    [HUG#1383439]          Financial Statement Release: http://hugin.info/132025/R/1383439/342337.pdf